Indivior Inc To Pay $10 Million After Settling FTC Charges It Used Anticompetitive Tactics To Impede Competition From Lower-Cost Suboxone Generics
This week, Indivior Inc. agreed to pay $10 million to settle Federal Trade Commission charges that it had violated antitrust laws through a deceptive scheme to stop lower-priced generic competition with its opioid replacement therapy drug Suboxone. The purposed stipulated order bars Indivior from engaging in similar behavior in the future. Suboxone is used to … Read more